Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Now, a groundbreaking study from researchers at Boston Children’s Hospital and Harvard Medical School is offering a potential ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.

Healthcare company Organon & Co. (OGN) said on Wednesday that it is discontinuing the development of its investigational ...

Organon said on Wednesday it will the stop development of an experimental treatment it acquired through its purchase of Forendo Pharma, after the drug failed to reduce pelvic pain in women with ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

A landmark 30-year study of over four million women in England has revealed that women with endometriosis-associated ...

Four in five people living with chronic pain are hiding their condition – held back by stigma, ineffective treatments, and ...

Researchers are developing promising suppression systems for painful conditions—even an app on your phone that turns the pain ...

The Global Endometriosis Treatment Market is expected to reach at a CAGR of 10.62% during the forecast period 2025-2033. Sai Kiran DataM Intelligence 4Market Research +1 877-441-4866 ... Visit us on ...

Then, using a mouse model that mimics both the pain and tissue damage seen in human endometriosis, they administered four drugs—all currently FDA-approved for treating migraines—known to ...